ZW251 for Liver Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a new treatment, called ZW251, is safe and effective for individuals with advanced liver cancer. The treatment, an antibody-drug conjugate (a targeted cancer therapy), aims to attack cancer cells. It is specifically for those with hepatocellular carcinoma (HCC) that cannot be surgically removed or treated with a transplant. Ideal candidates have liver cancer that has spread or is locally advanced, and they must have good liver function and overall health. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that ZW251 is likely to be safe for humans?
Research shows that ZW251, a new treatment for liver cancer, is still in the early stages of testing. It is currently in Phase 1, which means testing in people has just begun. In prior lab and animal tests, ZW251 demonstrated strong effects against liver cancer. However, there is not yet enough information from human studies to determine its exact safety profile.
Phase 1 trials primarily focus on safety and finding the right dose, so researchers closely monitor any side effects. Since ZW251 is still under investigation, information about its tolerability remains limited. Participants in this trial will contribute to gathering important safety data.12345Why do researchers think this study treatment might be promising?
Most treatments for liver cancer involve chemotherapy or targeted therapies that attack cancer cells directly. But ZW251 works differently, targeting specific proteins involved in cancer cell growth, which could offer a more precise approach to treatment. Researchers are excited because this unique mechanism of action may lead to fewer side effects and improved effectiveness compared to existing options. If successful, ZW251 could provide a new hope for patients who have limited responses to current treatments.
What evidence suggests that ZW251 might be an effective treatment for liver cancer?
Research has shown that ZW251, the investigational treatment studied in this trial, holds strong potential for treating liver cancer. In early laboratory and animal studies, ZW251 performed well against various liver cancer types. These studies used patient-derived cancer samples grown in labs to closely mimic real tumors. The treatment targets a protein called glypican-3 (GPC3), often found in liver cancer cells, making it a promising method to attack and destroy these cells. Although human trial data is limited, early results are encouraging for its effectiveness against hepatocellular carcinoma (HCC), a common form of liver cancer.12346
Who Is on the Research Team?
Maggie Weinstein, MD, PhD, MPH
Principal Investigator
Zymeworks BC Inc.
Are You a Good Fit for This Trial?
This trial is for adults with advanced liver cancer that can't be removed by surgery or treated with a transplant. They should have measurable disease, confirmed HCC diagnosis, be relatively active (ECOG score of 0 or 1), and have good liver function (Child-Pugh Class A).Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Part 1 of the study will evaluate the safety and tolerability of ZW251 in HCC
Dose Optimization
Part 2 of the study will further assess safety and potential anti-tumor activity of the ZW251 established recommended doses in HCC
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ZW251
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zymeworks BC Inc.
Lead Sponsor